Quantcast

Latest Behring Stories

2014-05-20 08:34:27

Eligible Participants to Receive Payment Assistance with Out-of-Pocket Costs Associated with Hizentra® Therapy in the United States KING OF PRUSSIA, Pa., May 20, 2014 /PRNewswire/ -- People managing primary immunodeficiency (PI) with CSL Behring's Hizentra(®) (Immune Globulin Subcutaneous [Human]) may now be eligible for financial support through the Hizentra(®) Co-Pay Relief Program. The new program offers eligible U.S. patients up to $4,000 per year to be applied toward Hizentra...

2014-05-14 08:31:29

Third annual awareness day shines a light on rare, potentially life-threatening condition KING OF PRUSSIA, Pa., May 14, 2014 /PRNewswire/ -- As a Diamond Sponsor of HAE Day on May 16, 2014, CSL Behring is proud to continue its partnership with HAEi, the International Patient Organization for C1 Inhibitor Deficiencies, and patient organizations throughout the world. HAE, or, hereditary angioedema, is a rare, potentially fatal swelling disorder caused by a deficiency of C1-INH, a type of...

2014-05-09 12:25:57

-- Leading-edge science at the core of $250 million expansion to drive long-term growth in promising bleeding disorders portfolio KING OF PRUSSIA, Pa., May 9, 2014 /PRNewswire/ -- CSL Limited (ASX:CSL), parent company of CSL Behring which is based in King of Prussia, PA, today opened the CSL Behring Biotechnology Manufacturing Facility in Melbourne, Australia. The new facility, located adjacent to the site's manufacturing plant for plasma products, is the centerpiece of CSL's...

2014-05-02 08:25:41

KING OF PRUSSIA, Pa., May 2, 2014 /PRNewswire/ -- CSL Behring today announced that the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the efficacy, safety and pharmacokinetics of its novel investigational recombinant factor VIII single chain (rVIII-SingleChain) for the treatment of previously treated children (up to age 11 years) with severe hemophilia A. The study site for this first enrollment is Malaysia. A minimum of 25 previously treated...

2014-04-17 08:28:23

Donated coagulation factor supports WFH Global Alliance for Progress program KING OF PRUSSIA, Pa., April 17, 2014 /PRNewswire/ -- CSL Behring announced today that the company will continue its ongoing commitment to the global coagulation disorders community with a donation of product to the World Federation of Hemophilia (WFH). The donation, provided in connection with World Hemophilia Day on April 17, supports WFH's Global Alliance for Progress (GAP) program aimed at improving the...

2014-03-24 12:25:01

KING OF PRUSSIA, Pa., March 24, 2014 /PRNewswire/ -- Navigating the complexities of the Affordable Healthcare Act (ACA) can be challenging, particularly where patients with chronic medical disorders such as hemophilia and von Willebrand disease are concerned. CSL Behring is awarding a Local Empowerment for Advocacy Development (LEAD) grant to help bleeding disorder patients develop a clearer understanding of ACA and potential areas of concern....

2014-03-01 12:20:36

Analysis also reveals decrease in emergency room visits and hospitalizations SAN DIEGO, March 1, 2014 /PRNewswire/ -- Findings announced by CSL Behring today show that current hereditary angioedema (HAE) treatment options, such as C1 Esterase Inhibitor (C1-INH) concentrate, are allowing for greater patient satisfaction, higher rates of home treatment and a decrease in the number of hospitalizations and visits to the emergency room. HAE is a rare, potentially fatal swelling disorder...

2014-02-20 08:32:30

Year-round charitable giving includes over $700k to United Way KING OF PRUSSIA, Pa., Feb. 20, 2014 /PRNewswire/ -- You can tell a lot about a company and its employees by the way they give back to the community. CSL Behring, its subsidiary, CSL Plasma and their employees do just that, year-round, supporting a wide range of organizations that provide services to people in need. http://photos.prnewswire.com/prnvar/20100914/PH63692LOGO The annual United Way campaign is the company's single...

2014-02-20 08:32:25

International study by CSL Behring is world's first placebo-controlled phase III trial to examine subcutaneous administration of C1-INH for use in treating rare, sometimes life-threatening, condition KING OF PRUSSIA, Pa., Feb. 20, 2014 /PRNewswire/ -- CSL Behring today announced it has enrolled the first patient in COMPACT, an international phase III study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in patients with frequent hereditary...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related